Theravance plans strategic review, including possible sale, after drug trial failure
ReutersMar 3, 2026 1:46 PM
March 3 (Reuters) - Theravance Biopharma TBPH.O said on Tuesday it is initiating a strategic review, including a possible sale of the company, after its experimental drug to treat a type of blood pressure disorder failed to meet the main goal in a late-stage study.
The drug ampreloxetine was being tested in people with multiple system atrophy, a rare disease that can cause a dangerous drop in blood pressure when standing.
Theravance said patients taking the drug did not report a meaningful improvement in symptoms compared with those on a placebo.
The company said it is working with investment bank Lazard on the review, but added there was no guarantee any deal will happen.
Shares of the company were halted in premarket trading.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Partnering With Lumentum and Coherent, Can Nvidia’s $4 Billion CPO Bet Support the Future of AI Computing Power?
TradingKey - On Monday, March 2 local time, NVIDIA (NVDA) announced that it has entered into a deep strategic partnership with optical technology manufacturers Lumentum (LITE) and Coherent (COHR). NVIDIA will invest $2 billion in each company, totaling a massive $4 billion investment. This move advances NVIDIA's strategic layout in the field of AI data center network architecture to a new stage.TradingKey
8 hours ago
Bitcoin Stuck in Range Struggle, Can US-Iran Conflict Help a Breakout?
As the US-Iran conflict continues to escalate, Bitcoin prices remain range-bound and are losing their war premium.TradingKey
12 hours ago
JPMorgan Warns Hormuz Blockade Risks Oil Shutdown in 25 Days, But How Will the US-Iran Conflict Shape Global Oil Prices?
TradingKey - Following the announcement on the night of February 28 banning all vessels from passing through the Strait of Hormuz, JPMorgan Chase issued a warning: if the Strait of Hormuz is completely blocked, the combined onshore and offshore storage capacity of Middle Eastern oil-producing nationTradingKey
Mon, Mar 2
US-Iran Conflict Ignites, Global Arms Race Heats Up, Will Defense Stocks See a New Round of Gains?
TradingKey - On February 28 local time, the United States and Israel launched joint large-scale airstrikes against Iran, targeting its nuclear facilities, missile industry, and naval forces. This marks another sharp escalation in the conflict following the US military strikes on Iranian nuclear facilities in June last year. The military operation not only exacerbates already strained geopolitical tensions but has also sent shockwaves through global capital markets, which is expected to further boost defense stocks.TradingKey
Mon, Mar 2
The Hyperliquid Phenomenon: HYPE Ecosystem’s Path to $250
Explore the Hyperliquid (HYPE) 2026 outlook as it evolves from a high-speed DEX into a powerful Layer 1 ecosystem. This analysis breaks down the $2.95 trillion trading volume, the impact of the HIP-4 prediction market launch, and the HYPE token's technical resilience at the $31.77 level amidst globaTradingKey
Mon, Mar 2
